指南与共识血栓与止血

迎接挑战:关于胎儿和新生儿同种免疫性血小板减少症的国际德尔菲共识研究

Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia.
指南 / 共识 · Lancet Haematol · 2025-01-01

该德尔菲研究邀请欧洲、美国、加拿大和澳大利亚的胎儿和新生儿同种免疫性血小板减少症(FNAIT)改良德尔菲专家组成员参与,经三轮在线问卷和一次现场会议,最终35条陈述中25条(71%)达成共识,专家同意使用抗HPA-1a抗体水平识别高危FNAIT妊娠但未定义截断值,并在仅基于抗HPA-1a抗体水平测量的成本效益筛查方案设计上达成共识。

要点

  • 35条陈述中25条(71%)达成共识,共识阈值设为80%。
  • 专家同意使用抗HPA-1a抗体水平识别高危FNAIT妊娠,但未定义截断值。
  • 专家就仅基于抗HPA-1a抗体水平测量的成本效益筛查方案设计达成共识。

核心结论

  • 该德尔菲研究促进了国际知识共享,有助于澄清与照护标准认知相关的本地政策。

研究设计与样本

  • 邀请欧洲、美国、加拿大和澳大利亚的FNAIT改良德尔菲专家组成员参与,专业领域包括产科、新生儿科、儿科、实验室和输血医学、血液学、卫生技术评估及群体筛查相关管理。
  • 研究包括三轮在线问卷和一次于2023年4月在荷兰莱顿举行的现场会议,问卷由荷兰FNAIT专业中心专业人员与合著者共同制定。
  • 最终问卷包含35条关于当前管理和可能的产前FNAIT筛查方案的陈述,回答选项为同意、不同意、既不同意也不反对、知识不足,共识阈值设为80%。

主要发现

  • 三轮问卷后,35条陈述中25条(71%)达成共识。
  • 专家同意使用抗HPA-1a抗体水平识别高危FNAIT妊娠,但未定义截断值。
  • 专家就仅基于抗HPA-1a抗体水平测量的成本效益筛查方案设计达成共识。
  • 在静脉注射免疫球蛋白基础上加用糖皮质激素以及FNAIT妊娠的分娩方式两个方面观察到国际差异。

关键数值与推荐

  • 共识阈值设为80%。
  • 最终问卷35条陈述中25条(71%)达成共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition in which a fetus is at risk for severe thrombocytopenia, possibly resulting in intracranial haemorrhage, due to maternal alloantibodies formed against human platelet antigens (HPAs). Currently, no FNAIT screening programme exists. Pregnancies at risk of FNAIT are identified in individuals who have previously given birth to a child with FNAIT. Management of the condition differs depending on the country. A panel of experts in obstetrics, neonatology, paediatrics, laboratory and transfusion medicine, haematology, health technology assessments, and population screening-related administration who are members of the FNAIT Modified Delphi Expert Group from Europe, the USA, Canada, and Australia, were invited to participate in this study. This Delphi study included three rounds of online questionnaires, which were formulated by professionals from the Dutch FNAIT centre of expertise in collaboration with co-authors, and one live meeting in Leiden, the Netherlands in April, 2023. Funding for the live meeting in Leiden was obtained from the Dutch Research Council. The final questionnaire had 35 statements on current management and a possible antenatal FNAIT screening programme. Answer options were: agree, disagree, neither agree or disagree, and not sufficient knowledge. Consensus threshold was set at 80%. After three rounds of questionnaires, consensus was reached on 25 (71%) of 35 statements. The experts agreed on the use of anti-HPA-1a antibody levels to identify high-risk FNAIT pregnancies, although a cutoff value was not defined. The panel achieved consensus on the design of a cost-effective screening programme based only on anti-HPA-1a antibody level measurement. International differences were observed in case of two aspects: addition of corticosteroids to intravenous immunoglobulins and delivery mode in FNAIT pregnancies. This Delphi study facilitated sharing of international knowledge, which enabled clarification of local policies related to perceived standards of care.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Pothof R, van den Akker-van Marle EM, de Vos TW, et al. Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia. Lancet Haematol. 2025. PMID: 40175002. doi:10.1016/S2352-3026(25)00029-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。